Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Here it is!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(34)
•••
Comment by Wino115on Jan 11, 2022 4:54pm
104 Views
Post# 34305627

RE:RE:RE:RE:Here it is!

RE:RE:RE:RE:Here it is!Oh Man --thank the lord on that mistake! The funny thing is, it would fit the fact pattern unfortunately.  

realitycheck4u wrote: The broker who called me obviously needs help.  

Wino115 wrote: Wait!! --what is it? I see the date, but why would a broker call you about a deal?  

Wino115 wrote: Well, well.... This is a date that will live in infamy - Jan 11th, on the ONO anniversary!  An exact replica, wasting another opportunity to build an audience with US brokers.  Once again the same issue. Normal logic would make you think they would wait a few weeks/months to finalize 1a and get some positive momentum going in the share again!!!!!   So, we are left to wonder why they didn't do this and what they have disclosed to those new investors to get them interested in this again.  It's probably the exact same traders who will flip and no one new.  This is exasperating to say the least......  Time to open the cheap bottle, not the good one I was saving.  



realitycheck4u wrote: https://ca.investing.com/news/stock-market-news/brieftheratechnologies-announces-40-mln-boughtdeal-public-offering-of-units-2329888

 

 




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities